The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/IIa clinical study of 4th generation BTK inhibitor HBW-3220 capsules in patients with B-cell malignancies.
 
Ning Lee
Employment - Hyperway Pharmaceuticals
Leadership - Hyperway Pharmaceuticals
Stock and Other Ownership Interests - Hyperway Pharmaceuticals
 
Yong Mao
Employment - Hyperway Pharmaceuticals
Leadership - Hyperway Pharmaceuticals
Stock and Other Ownership Interests - Hyperway Pharmaceuticals
 
Qingchun Liu
Employment - Hyperway Pharmaceuticals
 
Huilai Zhang
No Relationships to Disclose
 
Zhiming Li
No Relationships to Disclose
 
Lihong Liu
No Relationships to Disclose
 
Ke-Shu Zhou
No Relationships to Disclose
 
Hui Zhou
No Relationships to Disclose
 
Liqun Zou
No Relationships to Disclose
 
Haiwen Huang
No Relationships to Disclose
 
Yu Yang
No Relationships to Disclose
 
Huangming Hong
No Relationships to Disclose
 
Xiaobing Huang
No Relationships to Disclose
 
Na Zhang
No Relationships to Disclose
 
Jishi Wang
No Relationships to Disclose
 
Fei Li
No Relationships to Disclose
 
Jiang Li
Employment - Hyperway Pharmaceuticals
Leadership - Hyperway Pharmaceuticals
 
Guanfeng Liu
Employment - Hyperway Pharmaceuticals
Stock and Other Ownership Interests - Hyperway Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Hyperway Pharmaceutical Company
 
Yingfu Li
Employment - Hyperway Pharmaceuticals
Leadership - Hyperway Pharmaceuticals
Stock and Other Ownership Interests - Hyperway Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Hyperway Pharmaceutical Company